Health officials say a potential new weapon in the fight against melanoma is showing promising results. Moderna and Merck say ...
The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate ...
Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.
1don MSNOpinion
Why Moderna’s mRNA cancer drug hype has gone too far
The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from ...
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...
Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...
CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results